ChIP-seq Defined Genome-Wide Map of TGFβ/SMAD4 Targets: Implications with Clinical Outcome of Ovarian Cancer
2011

Mapping TGFβ/SMAD4 Targets in Ovarian Cancer

Sample size: 153 publication 10 minutes Evidence: moderate

Author Information

Author(s): Brian A. Kennedy, Daniel E. Deatherage, Fei Gu, Binhua Tang, Michael W. Y. Chan, Kenneth P. Nephew, Tim H-M. Huang, Victor X. Jin

Primary Institution: The Ohio State University

Hypothesis

The study investigates the genome-wide binding patterns of SMAD4 in response to TGFβ stimulation in ovarian cancer cells.

Conclusion

The study identifies thousands of SMAD4 target genes in ovarian cancer and links TGFβ/SMAD signaling to patient survival outcomes.

Supporting Evidence

  • TGFβ stimulation alters SMAD4 binding patterns in ovarian cancer cells.
  • Identified SMAD4 target genes were predictive of patient survival.
  • Genome-wide mapping revealed distinct binding patterns for SMAD4.

Takeaway

Researchers looked at how a protein called SMAD4 binds to DNA in ovarian cancer cells when stimulated by a growth factor, which helps understand how this process affects cancer.

Methodology

The study used chromatin immunoprecipitation followed by sequencing (ChIP-seq) to identify SMAD4 binding loci in ovarian cancer cells.

Potential Biases

Potential biases may arise from the reliance on in silico mining of publicly available patient data.

Limitations

The study was limited by the availability of clinical data and the number of patient cohorts analyzed.

Participant Demographics

The study analyzed data from 153 ovarian cancer patients.

Statistical Information

P-Value

0.0471

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0022606

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication